Second-generation Antipsychotic Effect on Cognition in Patients with Schizophrenia--a Meta-analysis of Randomized Clinical Trials
Overview
Affiliations
Objective: To investigate the effect of second-generation antipsychotics on cognitive function in patients diagnosed with schizophrenia or schizoaffective disorder.
Method: Multiple-treatments meta-analysis model.
Results: On cognitive composite score, sertindole was superior to clozapine, effect size (ES) 0.87; 95% CI: 0.12-1.63, quetiapine, ES 0.75; 95% CI: 0.00-1.49, and first-generation antipsychotics (FGAs), ES 0.89; 95% CI: 0.14-1.64. Analyses on each cognitive domain showed clozapine, ES 0.37; 95% CI: 0.00-0.74, olanzapine, ES 0.31; 95%CI: 0.02-0.59, quetiapine, ES 0.34; 95% CI: 0.03-0.64, and FGAs, ES 0.51; 95% CI: 0.18-0.83 performing poorer on verbal working memory than ziprasidone, as well as FGAs performing poorer than risperidone, ES 0.31; 95% CI: 0.04-0.58. On executive function, sertindole performed better than clozapine, ES 0.82; 95% CI: 0.06-1.58, olanzapine, ES 0.81; 95% CI: 0.07-1.55, quetiapine, ES 0.76; 95% CI: 0.02-1.51, ziprasidone, ES 0.90; 95% CI: 0.14-1.67, and FGAs, ES 0.83; 95% CI: 0.08-1.58. On processing speed, FGAs performed poorer than sertindole, ES 0.97; 95% CI: 0.02-1.91, and quetiapine, ES 0.36; 95% CI: 0.01-0.72. On long-term verbal working memory, clozapine performed poorer than olanzapine, ES 0.41; 95% CI: 0.06-0.76. On verbal fluency, FGAs performed poorer than olanzapine, ES 0.26; 95% CI: 0.01-0.50, and clozapine, ES 0.44; 95% CI: 0.06-0.81. Lastly, FGAs, ES 0.41; 95% CI: 0.04-0.78, and clozapine, ES 0.44; 95% CI: 0.05-0.83, performed poorer on visuospatial skill compared to olanzapine.
Conclusion: The meta-analysis was able to detect some trends in the data analyzed, but did not show any drug having a uniform positive cognitive profile.
Clinical practice guidelines for assessment and management of cognitive impairment in schizophrenia.
Grover S, Mohapatra D, Vaitheswaran S, Mehta U, Venkatasubramanian G, Thirthalli J Indian J Psychiatry. 2025; 67(1):65-83.
PMID: 40046487 PMC: 11878460. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_690_24.
de-la-Higuera-Gonzalez P, Rodriguez-Toscano E, Diaz-Carracedo P, Gonzalez-Urrea M, Padilla-Quiles G, Diaz-Marsa M Eur Arch Psychiatry Clin Neurosci. 2025; .
PMID: 39903265 DOI: 10.1007/s00406-025-01961-w.
Moscou T, Veerman S Ther Adv Psychopharmacol. 2024; 14:20451253241302603.
PMID: 39650250 PMC: 11624563. DOI: 10.1177/20451253241302603.
[Cognitive impairments associated with schizophrenic psychoses : Diagnostics, course and therapy].
Kambeitz-Ilankovic L, Strube W, Baune B, Falkai P, Roll L, Leucht S Nervenarzt. 2024; .
PMID: 39589503 DOI: 10.1007/s00115-024-01773-8.
Guideline for pharmacological treatment of schizophrenia 2022.
Neuropsychopharmacol Rep. 2024; 45(1):e12497.
PMID: 39587785 PMC: 11666347. DOI: 10.1002/npr2.12497.